Binding of doxorubicin to sorcin impairs cell death and increases drug resistance in cancer cells by Genovese, Ilaria et al.
OPEN
Binding of doxorubicin to Sorcin impairs cell death and
increases drug resistance in cancer cells
Ilaria Genovese1, Annarita Fiorillo1, Andrea Ilari2, Silvia Masciarelli3, Francesco Fazi*,3 and Gianni Colotti*,2
Sorcin is a calcium binding protein that plays an important role in multidrug resistance (MDR) in tumors, since its expression
confers resistance to doxorubicin and to other chemotherapeutic drugs. In this study, we show that Sorcin is able to bind
doxorubicin, vincristine, paclitaxel and cisplatin directly and with high affinity. The high affinity binding of doxorubicin to sorcin
has been demonstrated with different techniques, that is, surface plasmon resonance, fluorescence titration and X-ray diffraction.
Although the X-ray structure of sorcin in complex with doxorubicin has been solved at low resolution, it allows the identification of
one of the two doxorubicin binding sites, placed at the interface between the EF5 loop the G helix and the EF4 loop. We show that
Sorcin cellular localization changes upon doxorubicin treatment, an indication that the protein responds to doxorubicin and it
presumably binds the drug also inside the cell, soon after drug entrance. We also demonstrate that Sorcin is able to limit the toxic
effects of the chemotherapeutic agent in the cell. In addition, Sorcin silencing increases cell death upon treatment with
doxorubicin, increases the accumulation of doxorubicin in cell nucleus, decreases the expression of MDR1 and doxorubicin efflux
via MDR1.
Cell Death and Disease (2017) 8, e2950; doi:10.1038/cddis.2017.342; published online 20 July 2017
The development of drug resistance is the leading cause of
chemotherapy failure in cancer treatment. Elucidation of the
mechanisms that confer simultaneous resistance to different
drugs with different chemical structures and molecular targets
– multidrug resistance (MDR) – has been a primary goal of
cancer biologists during the past decades. Chemotherapy is
the treatment of choice in metastatic cancer; by limiting drug’s
effectiveness, MDR represents a major obstacle to this option.
Cancer cells can adopt several strategies to evade death
induced by chemotherapeutic agents. These include changes
in apoptotic pathways, increased DNA damage repair, drug
inactivation, alteration of drug targets and increased expres-
sion of ABC transporters, able to pump xenobiotics (such as
toxins or drugs) out of cells.1 Many cancer cells express large
amounts of MDR1 (ABCB1, or P-glycoprotein 1), which
confers them MDR.2–4
Sorcin (SOluble Resistance-related Calcium-binding
proteIN) gene is located in the same chromosomal locus
and amplicon as the ABC transporters MDR1 andMDR3, both
in human and rodent genomes, and is highly conserved
among mammals. Sorcin was initially labeled ‘resistance-
related’, since it is co-amplified with MDR1 in multidrug-
resistant cells.5,6 While for years Sorcin overproduction was
believed to be a by-product of the coamplification of its gene
with P-glycoprotein genes,7 many recent reports have
demonstrated that Sorcin plays a role in MDR, and pointed
at a possible role as an oncoprotein.
Sorcin is one of the most highly expressed calcium-binding
proteins in many tissues, and part of the 5% most expressed
proteins of the human proteome (PaxDb). Importantly, Sorcin
is overexpressed in many human tumors and MDR cancers.8
The level of Sorcin expression in leukemia patients inversely
correlates with patients’ response to chemotherapies and
overall prognosis. In parallel, Sorcin is highly expressed in
chemoresistant cell lines and significantly upregulated in
doxorubicin-inducedMDR leukemia cell line K562/A02 over its
parent cells. Sorcin overexpression by gene transfection
increased drug resistance to a variety of chemotherapeutic
agents in K562 cells, SGC7901 cells, ovarian and breast
cancer. On the other hand, several studies have demonstrated
that inhibition of Sorcin expression by RNA interference led to
reversal of drug resistance in many cell lines.8
Recent data indicate that Sorcin participates in several
processes that might contribute to MDR in human cancers,
such as drug efflux regulation, apoptosis modulation and
epithelial-to-mesenchymal transition (EMT) control.8,9 Con-
flicting results are in literature on the effect of Sorcin
overexpression and silencing on MDR1 expression and
activity.10–13 A complete understanding of the mechanisms
and pathways by which Sorcin contributes to the MDR
phenotype of tumor cells and an assessment of the overall
diagnostic and therapeutic potential of sorcin in MDR are still
missing.
Recently we have solved the crystal structure of apo- and
calcium-bound human Sorcin, showing the mechanism of
activation of the protein.14 Upon calcium binding Sorcin
undergoes a large conformational change that exposes three
pockets, hydrophobic surfaces involving the EF loop and EF5
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hand (Pocket 1), EF2-EF3 (Pocket 2) and region EF1-EF3
(Pocket 3). This allows Sorcin to bind and regulate target
proteins in a calcium-dependent fashion.15–21
Here we demonstrate that Sorcin binds doxorubicin directly
and with high affinity and that it changes its cellular localization
upon doxorubicin treatment and limits the toxic effects of
doxorubicin in the cell; the low resolution structure of Sorcin in
complex with doxorubicin allowed the identification of at least
one chemotherapeutic drug binding site.We also demonstrate
that Sorcin silencing increases cell death upon doxorubicin
treatment, increases the accumulation of doxorubicin in cell
nucleus, decreases the expression of MDR1 and doxorubicin
efflux via MDR1.
Results
Sorcin binds doxorubicin and other chemotherapeutic
drugs with high affinity. For surface plasmon resonance
(SPR) experiments, two types of sensorgrams have been
measured. OneStep-SPR experiments show that Sorcin is
able to bind doxorubicin, paclitaxel and vinblastine, with high
affinity, in the submicromolar range (Figure 1,Supplementary
Figure S1); FastStep-SPR experiments (Figure 1a,
Supplementary Figure S2) can be fitted with two binding
sites, one in the nanomolar range and one in the low
micromolar range (KD1= 10 nM; KD2= 1 μM in the presence
of calcium; KD1=22 nM; KD2= 2 μM in the presence of
EDTA). Sorcin also binds cisplatin, with a KD= 1.7 μM (one
binding site, Supplementary Figure S1). Fluorescence titra-
tions (Figures 1b and c,Supplementary Figure S2) were
carried out by measuring the fluorescence at 280 nm upon
stepwise doxorubicin addition to Sorcin (Figure 1b) and to the
Sorcin calcium-binding domain (SCBD, Figure 1c), compris-
ing residues 32–198 of Sorcin. The fitting of fluorescence
titrations for both Sorcin and SCBD are compatible with 2
doxorubicin binding sites (Figure 1, Supplementary
Figure S2), with affinity constants in the same order of
magnitude with respect to those measured by SPR experi-
ments, that is, 1.4± 1 and 734±396 nM for SCBD and
0.9±0.5 and 511± 140 nM for Sorcin in the presence of
EDTA (1.2 and 360 nM; 0.9 and 318 nM for Sorcin, in the
presence of 1 and 5 mM magnesium, respectively): doxor-
ubicin binding occurs at the C-terminal calcium-binding
domain, since SCBD retains the binding sites. Signal shift
was not detected, indicating that the environment of
fluorophores did not change upon doxorubicin binding. The
value obtained for KD1 is lower than protein concentration,
condition that can cause an overestimation of the constant
and large errors. We could not lower protein concentration
due to the signal/noise ratio; however it can be assessed that
KD1 is not greater than estimated.
Therefore, Sorcin, which was previously shown to increase
resistance to a variety of chemotherapeutic agents, is able to
bind directly and with high affinity doxorubicin and other
chemotherapeutic drugs in vitro; this prompted further experi-
ments to understand how such binding may contribute to
increase drug resistance in cells as a function of its expression
in the cell.
Crystal structure of the Sorcin-doxorubicin complex.
Addition of 4 : 1 molar excess of doxorubicin to a clear,
transparent solution of concentrated apo-Sorcin determines
clouding of the solution, aggregation and precipitation of the
protein (similar to the precipitation observed upon calcium
addition), with formation of a red precipitate and the slow
growth of red-colored crystals (Figure 2a).
Crystals of different intensity of red color grew depending on
the amount of doxorubicin used for crystallization, ranging
from 0.5 : 1 (colorless) to 2 : 1 (pink) to 15 : 1 (red) molar
excesses. Emission spectra of the crystals grown from these
solutions were recorded at 100 K in the Bessy facility, exciting
at 473 nm. Changes in peaks intensity and a 25 nm red shift of
the bands in high-amount doxorubicin (red crystals) were
observed with respect to low-amount doxorubicin Sorcin
crystals (Supplementary Figure S3). These changes are likely
due to doxorubicin stacking to aromatic residues of the protein
or doxorubicin dimerization, once bound.22
We solved the structure of the complex between SCBD and
doxorubicin (doxo-SCBD) at quite low resolution (3.74 Å, PDB
accession: 5MRA). The asymmetric unit contains two dimers
(A–B and C–D). The structure contains 10 Mg2+ ions (3 bound
to monomer A, 2 to monomer B, 3 to monomer C, 2 to
monomer D). Doxorubicin is bound to the B monomer. The
protein structure is similar to apo-Sorcin and apo-SCBD (PDB
accessions: 4UPG, 1 GJY14,23) (Figure 2b). The super-
imposition between the Cα trace of doxo-SCBD with the Cα
Figure 1 Sorcin binds doxorubicin with high affinity in vitro. (a) SPR titration experiments in the presence of 500 μM CaCl2 and (b,c) fluorescence titration experiments in the
presence of 0.5 μM EDTA: Doxorubicin binding to Sorcin (b) and SCBD (c) monitored by intrinsic fluorescence quenching. Each protein was incubated for 3 min at 25 °C in the
presence of increasing concentration of ligand. The bars indicate the standard deviation for three independent experiments. The insets show the whole emission peak for each
sample from one representative experiment. Both Sorcin and SCBD contain two binding sites for doxorubicin, with affinities in the nanomolar and low micromolar range
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trace of apo-Sorcin yields an rmsd of 1.11 Å, indicating that the
structures are similar and therefore neither Mg2+ ions binding
nor doxorubicin binding are able to promote the conforma-
tional changes induced by calcium ions in Sorcin. In
accordance with binding experiments, doxorubicin binding
occurs at two sites. Inspection of the Fo-Fc electronic density
map allowed the identification of two peaks (Supplementary
Figure S4): one close to the EF5 hand, which does not bind
calcium in Sorcin and is responsible for dimer formation, and
the other close to the D-helix connecting the EF2 and EF3
sites at the interface between the two dimers. We succeeded
in modeling the doxorubicin molecule in the first site (close to
the EF5) whereas it was not possible to model the doxorubicin
molecule in the second site (close to the D helix) indicating
both the low occupancy of the site and the flexibility of the
doxorubicin molecule (Supplementary Figure S4). These sites
have been previously identified as Pocket 1 and Pocket 2, able
to bind protein targets, in another PEF protein, that is, PDCD6
(ALG-2).24
The binding of doxorubicin to SCBD in pocket 1 involves a
stacking interaction of the drug with the aryl ring of Tyr188 of
one monomer and interaction with Asp177, Gly182, Phe173
and Phe134 of the two-fold symmetry related monomer at the
dimeric interface (Figures 2b and c). In the second putative site
(pocket 2) doxorubicin likely interacts with Trp105 and
Phe134. Probably doxorubicin binding to the second site
would be facilitated by the binding of calcium ions which, as
previously described,14 induce a conformational change
promoting the movement of the D-helix and the exposure of
hydrophobic interfaces.
In the structure, magnesium is bound to EF3 and to part of
EF1 and EF2 sites, showing that in Sorcin the first three
EF-hands can bind not only calcium, but alsomagnesium, with
rather high affinity, and that EF3 is the site endowed with the
highest affinity for divalent cations, responsible for Sorcin
cation-dependent activation.
Sorcin localization responds to doxorubicin treatment.
In H1299 lung cancer cell line, Sorcin (green fluorescence)
localizes to cell membrane, nucleus, ER and cytosol, as
already observed in other cellular systems.17 Upon treatment
with doxorubicin, Sorcin localization changes with respect to
control: after 1-h doxorubicin treatment, cytosolic Sorcin
localization increases and nuclear, ER and membrane
localization decreases; the ratio of cytosol/(nuclear+ER)
Sorcin fluorescence increases by 77% (from 0.278 to
0.491, number of cells= 60, Po0.01, Figure 3). This is a
clear indication that Sorcin localization responds to
doxorubicin treatment and that Sorcin presumably binds
doxorubicin also in the cell, upon drug entry.
Figure 2 Sorcin calcium binding domain-doxorubicin complex. (a) Crystal and (b) crystal structure of Sorcin calcium binding domain-doxorubicin complex; (c) doxorubicin
binding site at EF5 (pocket 1), stacked to Tyr188
Figure 3 Sorcin localization changes upon doxorubicin treatment. Sorcin localization (green fluorescence) in (a) control H1299 cells and in (b) H1299 cells treated for 1 h with
0.6 μM doxorubicin. (c) ratio between cytosol/(nucleus+ER) fluorescence (n= 60 cells; Po0.01)
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Effect of Sorcin expression on doxorubicin uptake and
toxicity, and cell death. Sorcin is expressed at high levels in
human and in many cell lines (PaxDB). We have analyzed
Sorcin expression in different cell lines from lung, cervix and
breast cancers and we evidenced that Sorcin is expressed in
all tested cell lines, but the levels differ even by more than one
order of magnitude between different lines. In particular,
Sorcin is highly expressed in lung cancer cell lines Calu-1
and H1299, that we have selected for further studies, and in
breast cancer cell lines MDA-MB-231 and MDA-MB-468,
while low Sorcin expression levels were observed in lung
A549 and in cervical cancer HeLa cells (Figure 4).
Sorcin high level of expression occurs in cell lines rather
resistant to cell death upon treatment with doxorubicin, as
H1299, Calu-1 and MDA-MB-468 cells, while A459 and HeLa
cell lines, where Sorcin expression is lower by about 90%, are
more sensitive to doxorubicin treatment (Figure 4). To support
the relevance of Sorcin in doxorubicin treatment response, we
proceeded with Sorcin silencing experiments. In all tested cell
lines, siRNA cds3 effectively silences Sorcin expression, by at
least 85% after 24–48 h (Supplementary Figure S5A). In the
H1299 line, 94±3% silencing occurs. Interestingly the
silencing of Sorcin expression is also maintained upon
doxorubicin treatment (Supplementary Figure S5B).
Sorcin silencing by siRNA cds3 (versus control experiments
with scrambled siRNA) slightly increases cell death
(Figures 5a and b,Supplementary Figure S6), as shown by
both cell count and by flow cytometry experiments on cells
Figure 4 Sorcin expression versus cell death. (top) Western blot experiment showing the expression of Sorcin in lung carcinoma Calu-1, A459 and H1299 cells; cervix
adenocarcinoma HeLa; breast adenocarcinoma MDA-MB-468 and MDA-MB-231. (bottom) Cell death is increased upon 24 h doxorubicin (0.6 mM) treatment in A549 and HeLa
cells, where Sorcin expression level is reduced by480% with respect to H1299 cells
Figure 5 Sorcin silencing increases cell death upon treatment of H1299 cells with
0.6 mM doxorubicin. (a) Cell count and (b) cell death percentage upon treatment of
H1299 cells with scrambled siRNA or Sorcin siRNA in control and doxorubicin-
treated cells
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stained with Sytox blue, a cyanine dye that is completely
excluded from live eukaryotic cells.
Upon Sorcin silencing, doxorubicin-dependent cell death is
markedly increased in H1299 cells (Figure 5): upon treatment
with scrambled siRNA and 0.6 μMdoxorubicin, the percentage
of deadH1299 cells increases from 3.4% (control) to 4.6% and
16.3% (24 and 48 h after doxorubicin treatment, respectively),
while upon treatment with Sorcin-directed siRNA and 0.6 μM
doxorubicin, the percentage of dead H1299 cells increases
from 4.5% (control) to 10.3% and 29.7% (+124% and +82%,
24 and 48 h after doxorubicin treatment, respectively).
Further, Sorcin silencing increases doxorubicin entry in
H1299 cell nuclei by 140% as shown by analysis of confocal
microscopy experiments (Figures 6a and b). FACS experi-
ments (Figure 6c,Supplementary Figure S7) show that upon
treatment with scrambled siRNA and 0.6 μM doxorubicin, the
percentage of doxorubicin incorporation increases from 0.4%
after 30 min to 3.4% after 1 h to 49.6% after 3 h doxorubicin
treatments, while upon treatment with Sorcin-directed siRNA
and 0.6 μM doxorubicin, the percentage of doxorubicin
incorporation increases from 0.8% after 30 min to 7.1% after
1 h to 72.7% after 3 h doxorubicin treatments (+100%, +109%,
+47%, respectively). After 5 h incubation with doxorubicin, the
buffering capacity of Sorcin is almost lost (Supplementary
Figure S7).
In the presence of high levels of Sorcin, doxorubicin is
therefore prevented from entering the nuclei of H1299 cells,
and the cells are protected from drug-dependent DNA
damages.
Sorcin protects cells, while Sorcin silencing increases
doxorubicin-dependent Poly(ADP-ribose)polymerase (PARP)
cleavage (Figure 6d,Supplementary Figure S8), an apoptotic
marker. In cells treated with Sorcin-directed siRNA, 48 h after
treatment with 0.6 μM doxorubicin, the levels of cleaved PARP
are higher than in control cells. An even higher increase of
doxorubicin-dependent PARP cleavage upon Sorcin silencing
in doxorubicin-treated cells can be measured by calculating
the ratio between the intensities of cleaved versus full-
length PARP.
Effect of Sorcin expression on MDR1 expression and
activity. The effect of Sorcin expression on doxorubicin
uptake and toxicity can be explained in part by the direct
binding of doxorubicin by Sorcin, that may prevent the drug
entry in the nucleus. However, doxorubicin is also a substrate
of the efflux pump MDR1,2 whose gene is located in the same
amplicon of Sorcin gene.5 Conflicting results are in literature
on the effect of Sorcin expression on MDR1 expression and
activity.10–13
Figures 6e and f show that Sorcin silencing decreases both
MDR1 expression and activity in H1299 cells, as already
demonstrated in A549 cells25 by about 40%. In cells treated
with Sorcin-directed siRNA the MDR1-mediated efflux of
rhodamine123 is substantially decreased with respect to
control cells treated with scrambled siRNA, showing a
Figure 6 Sorcin silencing increases doxorubicin accumulation in H1299 cells. (a) confocal microscopy images, showing the nuclear accumulation of doxorubicin upon 3 h
treatment in H1299 cells treated with scrambled siRNA (top) or with Sorcin siRNA (bottom); (b) nuclear doxorubicin incorporation by fluorescence quantification (n= 60 cells;
Po0.0001); (c) time-dependent quantification of doxorubicin incorporation in H1299 cells by FACS; (d) upon 48 h doxorubicin treatment, in Sorcin-silenced cells PARP cleavage
is increased with respect to control cells (n= 3, Po0.01). Sorcin silencing decreases MDR1 activity and expression with respect to control cells: (e) Rhodamine123 fluorescence
is increased (and therefore its efflux is decreased) and (f) MDR1 expression is decreased in Sorcin-silenced H1299 cells with respect to control cells (n= 3, Po0.001)
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decrease of the activity of MDR1 in Sorcin-silenced cells
(Figure 6e,Supplementary Figure S9): the level of intracellular
rhodamine123 in H1299 cells treated with Sorcin-directed
siRNA is increased by 27, 51 and 67% (upon 30 min, 1 h and
2 h incubation with the MDR1 substrate, respectively) with
respect to control cells.
MDR1 expression level is also strongly decreased by Sorcin
silencing: in cells treated with Sorcin-directed siRNA, a 45%
decrease in MDR1 level occurs with respect to H1299 control
cells (Figure 6f, Supplementary Figure S10).
Discussion
The high level of expression of Sorcin in many tumors,
especially the MDR ones, the inverse correlation of Sorcin
expression with patients’ response to chemotherapies and
overall prognosis, and reversal of drug resistance upon Sorcin
expression by RNA interference have recently struck the
attention of many scientists. In particular, Sorcin has been
shown to be upregulated in doxorubicin-induced MDR K562/
A02 leukemia cells over their parent cells, and Sorcin
overexpression has been demonstrated to increase drug
resistance to doxorubicin, etoposide, homoharringtonine,
vincristine, taxol, cisplatin and 5-fluorouracil in several cancer
cells.6,26–32 Further, many studies have demonstrated Sorcin
participation in several processes, such as drug efflux
regulation, apoptosis modulation and EMT control, that might
contribute to the onset of MDR in human cancers.8,9
However, the molecular basis of Sorcin-linked processes
that determine MDR has not been elucidated yet.
Here, we show for the first time that Sorcin is itself able to
bind directly and with high affinity chemotherapeutic agents
able to induce Sorcin-dependent MDR, such as cisplatin,
vinblastine, paclitaxel and in particular doxorubicin. SPR and
fluorescence titration experiments demonstrated that Sorcin
binds doxorubicin with high affinity and that there are at least
two doxorubicin-binding sites. The low resolution X-ray
structure of the complex allowed the identification of at least
one of these sites. Doxorubicin binds to regions that in
PDCD6, structurally similar to Sorcin, are involved in ALIX-Abs
peptide binding:24 binding occurs with 100% occupancy and
high affinity to Pocket 1 and with lower occupancy to Pocket 2.
Sorcin can therefore use the same pockets in different
fashions: they not only can bind calcium channels and other
proteins (RyR receptors, SERCA, NCX1), and regulate their
activity, thereby increasing Ca2+ accumulation in the endo-
plasmic (ER)/sarcoplasmic reticulum (SR), and increasing
resistance to ER stress,17,19,20,21,33,34 but can also bind
chemotherapeutic drugs with high affinity, decreasing
doxorubicin-dependent toxicity and cell death. In addition,
the present study shows that in H1299 cells expressing high
Sorcin levels, upon doxorubicin treatment Sorcin acquires a
more diffused cytosolic pattern, implying that doxorubicin can
be bound and sequestered by Sorcin (which is one of the most
expressed calcium-binding proteins) in the cytosol, before it
can translocate to the nucleus and exert its toxic effects at
cellular level.
These experiments contribute to elucidate the mechanisms
of drug resistance to chemotherapeutic agents in highly
Sorcin-expressing cells. Doxorubicin binds at the D-helix
connecting EF2 and EF3 sites of Sorcin, thereby covering this
area and impairing the Trp105-based interaction with its
targets located on cell membranes and ER surface14,16,21,35,36
and at Tyr188 and Arg174 residues, belonging to the putative
Nuclear Localization Sequence of Sorcin,17 thereby hamper-
ing Sorcin translocation to nucleus.
Doxorubicin sequestration impairs its chemotherapeutic
action, based on drug entry in the nucleus and its intercalation
in the DNA, and allows its MDR1-based extrusion. Possibly, in
a first phase, MDRmay depend predominantly on doxorubicin
sequestration. In the longer term, sequestration reaches
saturation, and MDR depends predominantly on the higher
MDR1-based extrusion.
We also show that when Sorcin expression is decreased,
the cells become sensitive to doxorubicin: the chemother-
apeutic drug can accumulate in the nucleus, where it exerts
cytotoxic effects by inhibiting topoisomerase II, thereby
generating free radicals and DNA damages, and activating
death pathways via activation of caspases, disruption of
mitochondrial membrane potential or mitotic catastrophe
accompanied by senescence-like phenotype.37 Chemother-
apeutics binding to Sorcin is a fast process that results in fast
cellular response to drug administration: Sorcin, one of the
most highly expressed calcium-binding proteins, can act as a
buffer for drugs, within a limited time span. Sorcin is a signaling
protein, because of its ability to respond rapidly to calcium
binding and, as we have demonstrated, to other molecules,
such as doxorubicin. In addition, alteration of the cellular levels
of Sorcin is a slower process, that impacts on MDR1
expression and that results in another mechanism of Sorcin-
dependent drug resistance: Sorcin overexpression induces
MDR1 expression via a cAMP-response element (CRE) of the
MDR1 gene, and therefore through activation of the CREB
pathway, by increasing CREB1 phosphorylation and the
binding of CREB1 to the CRE sequence of mdr1 promoter.13
Sorcin silencing determines a decrease of activity and
expression of MDR1, that pumps doxorubicin and many other
drugs outside of the cell, in line with data from other resistant
lung carcinoma cells or other tumors.13,25 Sorcin silencing,
combined to doxorubicin treatment, make cells prone to death.
Sorcin also participates in other mechanisms related to
oncogenesis and MDR onset, since it increases escape from
apoptosis, by preventing ER stress and the unfolded protein
response, by upregulating Bcl-2 and decreasing Bax
expression.17,33,38–40
The structure of doxorubicin-bound Sorcin deserves some
comments. Doxorubicin binding increases the disorder of the
crystal and decreases the resolution of the structure with
respect to those from unliganded protein. Addition of
doxorubicin to a solution of concentrated apo-Sorcin deter-
mines clouding of the solution, aggregation and precipitation
of the protein, followed by formation of a red precipitate and the
slow growth of red-colored crystals. However, the structure of
the Sorcin-doxorubicin complex is very similar to that of the
apo protein, possibly because of the presence of magnesium
in the crystallization solution. Magnesium binds to EF1, EF2
and EF3, in line with the affinity for calcium, which follows the
order EF34EF24EF1.36 While calcium binding to Sorcin
determines a large conformational change and protein
activation, neither magnesium binding nor doxorubicin binding
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alters the structure. This can be due to the smaller ionic radius
of magnesium with respect to calcium, and to crystal lattice
forces that may favor an apo-like conformation. Generally
speaking, calcium-dependent regulation of cellular activities is
based on transient and/or local increase of Ca2+ concentration
from 100 nM to low micromolar, while Mg2+ concentration
remains constant at about 0.5–2 mM, that is, 2–4 orders of
magnitude higher than Ca2+. Usually EF-hand proteins
discriminate against Mg2+, being evolved to take advantage
of the larger ionic radius and the less stringent demands on
coordination ligands of Ca2+.41 Sorcin, at least in conditions
where Mg2+ is very concentrated, is able to bind with full
occupancy this ion. However, possibly calcium binding can
elicit conformational changes that may lead to a better
exposure of doxorubicin-binding pockets.
Overall our study demonstrates that Sorcin is able to bind
directly and with high affinity doxorubicin and other che-
motherapeutic drugs, and that this contributes to the genera-
tion of the MDR phenotype. This work, together with other
recent papers, shows that Sorcin can be a useful marker of
MDR and may represent a therapeutic target for reversing
tumor MDR.
Materials and Methods
Surface plasmon resonance (SPR) experiments. SPR experiments
were performed with a SensiQ Pioneer apparatus. Wild-type human Sorcin was
immobilized via amine coupling onto a COOH5 sensorchip, previously chemically
activated by 100 μl injection of a 1 : 1 mixture of N-ethyl-N′-3-(diethylaminopropyl)
carbodiimide (200 mM) and N-hydroxysuccinimide (50 mM). Immobilizations were
carried out in 20 mM sodium acetate at pH 4.5; the remaining ester groups were
blocked by injecting 100 μl of 1 M ethanolamine hydrochloride at pH 9.5.
The amount of immobilized Sorcin was detected by mass concentration-
dependent changes in the refractive index on the sensorchip surface, and
corresponded to about 5000 resonance units (RU).
Samples of analytes (doxorubicin, cisplatin, vinblastine and paclitaxel) were
dissolved in 100% DMSO at a concentration of 10 mM, and subsequently diluted in
sterile HEPES 20 mM, pH 7.4, NaCl 150 mM, 500 μM CaCl2 (or EDTA) 0.005%
surfactant P-20 to yield 2% DMSO final concentration (HSP-2%D buffer) and final
drug concentration: 200 μM. Further dilutions and all the experiments were carried
out at 25 °C in degassed HSP-2%D buffer.
For FastStep experiments, the analytes were automatically diluted in HSP-2%D
and injected by seven serial doubling steps (step contact time= 30 s, nominal flow
rate= 100 μl/min). At the following time points: (1) 0–30 s; (2) 31–60 s; (3) 61–90 s;
(4) 91–120 s; (5) 121–150 s; (6) 151–180 s; (7) 181–198 s, analyte concentrations
were: (1) 1.25 μM; (2) 2.5 μM; (3) 5 μM; (4) 10 μM; (5) 20 μM; (6) 40 μM; (7) 80 μM.
For OneStep experiments, Taylor dispersions were exploited to generate analyte
concentration gradients that provide high-resolution dose response in single
injections. Full analyte titrations were recorded in HSPC-2%D over four orders of
magnitude in concentration, up to 80 μM.
In both FastStep and OneStep experiments, the increase in RU relative to baseline
indicates complex formation between the immobilized Sorcin ligand and the analytes.
The plateau region represents the steady-state phase of the interaction. The
decrease in RU after 198 s in FastStep experiments, or after 350 s in OneStep
experiments, indicates analyte dissociation from the immobilized Sorcin after
HSP-2%D buffer injection. As a negative control, sensor chips were treated as
described above in the absence of immobilized Sorcin. Values of the plateau signal at
steady-state (Req) and full fittings with 1, 2 and 3 sites were calculated from kinetic
evaluation of the sensorgrams using the Qdat 4.0 program.
Fluorescence titrations. Static fluorescence measurements were performed
at 25 °C with a Horiba Fluoromax-4 spectrofluorometer using 1-cm path-length
quartz cuvettes (slit width: 5 nm in excitation and emission). Fluorescence
measurements were performed on Sorcin and SCBD, a shorter construct missing
the first 32 residues, at two different concentrations: 30 nM and 37 nM, in Tris-HCl
10 mM, pH 7.5 and EDTA (0.5 μM) or MgCl2 (1 mM or 5 mM). The excitation
wavelength was set at 280 nm and emission spectra were collected in the 300–
400 nm range. Triplicate samples were measured; each figure represents the
average of three experiments.
Maximum emission occurs at 340 nm for SCBD and 338 nm for Sorcin. Upon
doxorubicin addition, fluorescence quenching was observed to a maximum extent of
about 60% in saturating condition. For each sample fluorescence was measured after
3 min of incubation.
Since doxorubicin absorbs light at 280 nm, fluorescence measurements are
affected by the inner-filter effect. The following formula was employed for correction:
Fcor= Fobs10^[(Aex)/2], where Fcor and Fobs are the corrected and observed
fluorescence intensities, respectively, whereas Aex is the absorbance of each
concentration of ligand at 280 nm [IFE-correction]. The effect is negligible at the
concentrations of doxorubicin used (5–3000 nM). Data were fitted with the software
Qtiplot assuming two independent binding sites. The equation used for data fitting is
the weighted sum of two independent binging events: K((k+c+x)− sqrt((k+c+x)2–4cx))/
(2c)+H((h+c+x)− sqrt((h+c+x)2–4cx))/(2c), where c is protein concentration, k and h
are the two binding constants, K and H are the fraction of signal due to each
binding event.
Crystallization, data collection and structure solution. Crystal-
lization experiments were performed with both human Sorcin and SCBD. Automated
crystallization screening and by-hand optimization were carried out at 298 K by
vapor diffusion method.
At first soaking technique was attempted but, while doxorubicin is deep red, the
crystals stayed uncolored; then we moved to co-crystallization. Since Sorcin
precipitates in presence of doxorubicin excess, trials were set up by adding the ligand
to the crystallization drop (0.4 μl of 0.5 mM protein+0.4 μl of reservoir+0.1 μl of
30 mM doxorubicin) to a ligand/protein ratio of about 15. Colored crystals, from light
pink to red, grew in many conditions but most of them resulted in poor diffraction. The
best data set collected was at 3.7 Å resolution, from a SCBD crystal grew in 0.2 M
MgCl2, 0.1 M Tris-HCl pH 7, 2.5 M NaCl. The crystals were cryoprotected by adding
40% w/v glucose to the mother liquor.
A single wavelength (0.9677 λ) data set was collected at ESRF at 100 K on the
ID30-A3 MASSIF3 beamline equipped with a Eiger-X-4M detector and processed
with XDS.42 Crystal parameters and data collection statistics are reported in Table 1.
The structure was determined by molecular replacement with the program
MOLREP43 (CCP4 suite) using the structure of the calcium-free human Sorcin
Table 1 Crystal parameters, data collection statistics and refinement statistics
PDB code 5MRA
Space group P21 21 21
Cell parameters (Å) a= 92.36, b= 104.98,
c=113.42
Asymmetric unit, residues Tetramer, 166 per
monomer
N° of bound ions 10 Mg++
Data reduction
Resolution range (Å) 48.31–3.74 (3.96–3.74)
Unique reflections 11800 (1845)
Completeness (%) 99.0% (97.2%)
Redundancy 6.53 (6.47)
Rmerge (%) 10.2 (113.3)
CC(1/2) 99.9 (64.7)
I/σ(I) 11.81 (1.45)
Data refinement
Resolution range (Å) 48.31–3.74 (3.83–3.74)
Rcryst (%) 19.6 (35)
Rfree (%) 28.5 (37)
rms (angles) (°) 1.324
rms (bonds) (Å) 0.01
Wilson B-factor (Å2) 162.2
Residues in core regions of the
Ramachandran plot (%)
90
Residues in allowed regions of the
Ramachandran plot (%)
10
Values in parentheses are for the highest-resolution shell
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(PDB entry 4UPG) as search model. Refinement was performed using the maximum-
likelihood method with the program REFMAC44 and model building with the program
Coot.45
Fluorescence emission spectra of SCBD-doxorubicin crystals were collected at
ESRF ID29S at 100 K and excitation wavelength 473 nm. The experimental setup is
described in more detail in a paper by Royant et al.46
Cell cultures and western blots. H1299, Calu-1, A459 human lung
carcinoma, HeLa human cervix adenocarcinoma, MDA-MB-468 and MDA-MB-231
breast adenocarcinoma cell lines were cultured in DMEM medium
(Gibco, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) with 10% FBS
(v/v) and 5% Penicillin/Streptomycin (v/v) at 37 °C in a balanced air humidified
incubator with 5% CO2.
The cells were lysed in a 2% SDS lysis buffer (25 mM Tris-HCl at pH 7.5, 100 mM
NaCl, 3 mM EDTA, 7% glycerol) with: NaF 1000 × , NaVO3 100 × , Na4PO7 20 × ,
Aprotinin 1000 × , Leupeptin 1000 × , PMSF 100 × protease and phosphatase
inhibitors as final concentrations.
Extracts were sonicated for 10 s and centrifuged at 12 000 r.p.m. for 10 min to
remove cell debris. Lysates were quantified in proteins content with Pierce BCA
protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions.
Thirteen percent acrylamide-bisacrylamide SDS gel electrophoreses were run for
sorcin, and 7% SDS-PAGE were run for PARP and MDR1. Proteins lysate content
was checked by S-Ponceau staining. Western blotting analysis was performed with
the following antibodies: rabbit polyclonal anti-human sorcin (home-made14), mouse
monoclonal anti-PARP (Cell Signalling, Danvers, MA, USA, #9532), mouse
monoclonal anti-MDR1 (Santa Cruz Biotechnology, Heidelberg, Germany, sc-
13131), mouse monoclonal anti-tubulin (Sigma-Aldrich, Darmstadt, Germany, cat.
T5168) and mouse monoclonal anti-bactin (Santa Cruz Biotechnology, sc-81178).
Goat secondary anti-mouse and anti-rabbit antibodies conjugated to horseradish
peroxidase were used (Bio-Rad, Hercules, CA, USA, cat. 170-6515, 170-6516).
Immunostained bands were detected by chemiluminescence (Chemidoc, Bio-Rad).
Doxorubicin treatment and silencing for sorcin. We performed a
dose-response curve (0.1 μM, 0.3 μM, 0.6 μM, 1.0 μM); 0.6 μM is the dose resulting
in the best evaluation of time-dependent accumulation, and is compatible with
doxorubicin plasma concentration 15 min to 2 h after treatment of many different
types of cancer.47 Doxorubicin concentration (0.6 μM) was used for most
experiments. H1299 cells were transfected with a solution composed by Optimem
medium (Gibco, Invitrogen, Thermo Fisher Scientific), Lipofectamine RNAimax
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA, cat.13778-030) and a final
concentration of 500 pM siRNA for sorcin (CDS3 and 3′UTR) (IDT sequence to
CDS3-exon3: 5′-GAUAGAUGCUGAUGAAUUGCAGAGA-3′; sequence to 3′UTR-
exon8: 5′-AGCUGUACACUUUCAAGUAAGAUCT)-3′, according to the manufac-
turer’s instructions. CDS3 siRNA silences both sorcin isoforms.18 After 48 h of
transfection, the medium was replaced with fresh DMEM (Gibco, Invitrogen, Thermo
Fisher Scientific) containing 0.6 μM doxorubicin. To evaluate doxorubicin incorpora-
tion, cells were treated with the drug in time-course experiments (30 min to 3 h
incubation for cytofluorimetry, 3 h and 5 h for confocal microscopy). The analysis of
biological effects of sorcin silencing was performed 24 h and 48 h after treatment.
Doxorubicin uptake (confocal microscopy and FACS). The uptake
of doxorubicin was evaluated through confocal microscopy and FACS (Fluorescent-
activated Cell Sorting) thanks to the autofluorescence of the molecule (excitation
wavelength 470 nm; emission wavelength 585 nm). To avoid cells drug saturation
the analysis was performed between 30 min and 5 h incubation.
For confocal microscopy, the medium was removed from the H1299 cells, then
washed with PBS. The cells were fixed in 2% paraformaldehyde for 10 min, washed in
PBS and incubated 7 min in TO-PRO-3 (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA, cat. T3605), dilution 1:3000. To avoid fluorophore quenching,
samples were covered with Vectashield Mounting Medium (Vector Laboratories,
Burlingame, CA, USA, cat. H-1000). Confocal images of slides were acquired at a
Leica laser scanning microscope TCS-SP2.
In order to have a quantitative readout on doxorubicin incorporation we performed
flow cytometry with CyAn ADP and Summit 4.3 software. The cells were dislodged
with trypsin 0.05% (Gibco, Invitrogen, Thermo Fisher Scientific), the emission of
doxorubicin was evaluated at 573 nm, and cells were gated as shown in
supplementary results. Data were analyzed with FCS4 express software.
Sytox blue assay and cell counts. To evaluate cell death we performed
assays with Sytox Blue Dead Cell Stain, for flow cytometry (Molecular Probes,
Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA, cat. MP34857). According
to the manufacturer’s instructions, 200 000 cells were sampled for each condition
and incubated 15 min at room temperature with Sytox blue 1:1000 dilution. The
samples were acquired at CyAn ADP by using Summit 4.3 software. The
fluorescence excitation of nucleic acids of dead cells was measured with 405 nm
violet laser light. Data were analyzed with FCS4 express software.
Lung, breast cancer cell lines and HeLa cells were treated 48 h with 0.6 μM
doxorubicin and the rate of Sytox blue incorporation was evaluated as
aforementioned.
Although this assay is very reliable, we evaluated the effect of sorcin silencing on
cell death with the traditional method of cell counts. The cells were dislodged diluted
1:1 with Trypan blue dye and counted in triplicates in a burker cell counting chamber.
Sorcin localization, confocal microscopy. H1299 cells were treated 1 h
with 0.6 μM of doxorubicin and processed as aforementioned for confocal
microscopy purpose. After paraformaldehyde fixation, cells were incubated 30 min
with a 1:200 dilution of primary antibody against Sorcin and, after PBS 1 × washing
steps, 30 min with Alexa Fluor 488 (Molecular Probes, Invitrogen, Thermo Fisher
Scientific)-conjugated secondary antibody against rabbit was used at a 1:500
dilution. A Leica laser scanning microscope TCS-SP2 device was used and images
were acquired with Leica confocal software.
Rhodamine123 incorporation. To ascertain whether sorcin silencing
affects MDR1 functionality in pumping out the drugs from the cell, we performed
a rhodamine123 accumulation assay. This dye is extruded outside the cells by
MDR1/MDR4 pumps. First the cells were silenced for 48 h, as mentioned, then a
time course accumulation assay was performed. We considered 250 000 cells each
time point (30 min, 1 h, 2 h) and the assay was carried out incubating the samples
at 37 °C in RPMI 1640 medium without and with 1 μM rhodamine123.
After incubation the samples were pelleted and washed twice in ice cold PBS 1 × .
Then they were analyzed at CyAn ADP by using Summit 4.3 software. The results
were evaluated with FCS4 express software.
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